Male infertility

Globozoospermia

CK2a1 levels are up-regulated 2-fold in human tumours compared to most other protein kinases.
 

TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Bladder carcinomas (%CFC= +78, p<0.0001); Brain oligodendrogliomas (%CFC= -71, p<0.009); Clear cell renal cell carcinomas (cRCC) stage I (%CFC= -91, p<0.0001); Ovary adenocarcinomas (%CFC= +72, p<0.034); Skin fibrosarcomas (%CFC= +103, p<0.014); and Skin melanomas - malignant (%CFC= +83, p<0.0006). The COSMIC website notes an up-regulated expression score for CK2a1 in diverse human cancers of 917, which is 2-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 183 for this protein kinase in human cancers was 3.1-fold of the average score of 60 for the human protein kinases.

Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.

Percent mutation rates per 100 amino acids length in human cancers: 0.08 % in 25183 diverse cancer specimens. This rate is very similar (+ 6% higher) to the average rate of 0.075 % calculated for human protein kinases in general.

Highest percent mutation rates per 100 amino acids length in human cancers: 0.3 % in 1093 large intestine cancers tested.

Most frequent mutations with the number of reports indicated in brackets: RH236R (5), R80C (3). These mutations are located in the kinase catalytic domain.

Only 1 deletion, and no insertions or complex mutations are noted on the COSMIC website.